Methods and compositions for improving gut microbiota population

Abstract

A method and a composition for improving gut micro biota structure, selectively increase a first gut microbiota population while simultaneously decrease a second gut micro biota population in a subject. The first gut micro biota population includes a short-chain fatty acid (SCFA)-producing bacterium and the second gut microbiota population includes an endotoxin-producing bacterium.

Description

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a national stage application of International application number PCT/CN2013/076709, filed Jun. 4 2013, titled “Methods and Compositions for Improving Gut Microbiota Population,” which claims the benefit of the filing date of Chinese Patent Application No. 201210185004.2 filed Jun. 6, 2012, the entire disclosure of which is incorporated by reference herein.

SEQUENCE LISTING

The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is Sequence listing.txt. The text file is about 87 KB, was created on Dec. 18, 2014, and is being submitted electronically via EFS-Web.

TECHNICAL FIELD

The present application relates to compositions and methods for improving gut microbiota populations and related application in drugs, nutritional supplements, health care products, food and beverage.

BACKGROUND

Unless otherwise indicated herein, the materials described in this section are not prior art to the claims in this application and are not admitted to be prior art by inclusion in this section.

Inside the human body lives a large number of symbiotic microbes, among which the gut microbiota acts asan important environmental factor to host health. There are more than 1000 species of bacteria, whose number exceeds 10 folds of the number of human cells, and whose gene number is about 150 folds of that in human cells. In this context, the human body as a “superorganism” made of host cells and symbioticmicrobes including gut microbiota, and the genome encoding a consortium of gut microbes (microbiome) is considered as the second human genome, also known as “humanmetagenome”. When human health status changes, the composition of symbioticmicrobes changes accordingly. Conversely, changes in the composition of symbioticmicrobes lead to the change in the human health status. Together, the diversity in human genome and the genome of gut microbiome affects immunity, nutrition, metabolism, and the health and disease status of the human host. However, up to now, it is not clear by what mechanisms the gut microbiota contribute to disease etiology and pathology, which type of bacteria is positively correlated with the health status of the host, and which type of bacteria is negatively correlated with the health status of the host.

SUMMARY

The following summary is illustrative only and is not intended to be in any way limiting. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent by reference to the drawings and the following detailed description.

In one aspect, the application provides methods for improving gut microbiota population. In one embodiment, the method includes administering to a subject a composition to increase a first gut microbiota population while simultaneously decrease a second gut microbiota population in the subject. The first gut microbiota population may include a short-chain fatty acid (SCFA)-producing bacteria. The second gut microbiota population may include an endotoxin-producing bacterium.

In another aspect, the application provides methods for screening a test compound that may be active in improving gut microbiota population. In one embodiment, the method includes administering to a control subject an effective amount of a control composition to increase a first gut microbiota population while simultaneously decrease a second gut microbiota population in the control subject, administering to a test subject an amount of a test compound, and comparing the gut microbiota population of the controlled subject with the gut microbiota population of the test subject. A similarity of at least about 80% is indicative that the test compound is active in improving gut microbiota population. The first gut microbiota population may include a short-chain fatty acid (SCFA)-producing bacteria. The second gut microbiota population may include an endotoxin-producing bacterium.

In a further aspect, the application provides compositions for improving gut microbiota population. In one embodiment, the composition is capable of selectively increasing a first gut microbiota population while simultaneously decreasing a second gut microbiota population in a subject. The first gut microbiota population may include a short-chain fatty acid (SCFA)-producing bacteria. The second gut microbiota population may include an endotoxin-producing bacterium. In one embodiment, the composition is administered to the subject at a dosage of from about 50 mg/kg body weight to about 400 mg/body weight and with once a day administration for at least two weeks.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other features of this disclosure will become more fully apparent from the following description and appended claims, taken in conjunction with the accompanying drawings. Understanding that these drawings depict only several embodiments arranged in accordance with the disclosure and are, therefore, not to be considered limiting of its scope, the disclosure will be described with additional specificity and detail through use of the accompanying drawings, in which:

FIG. 1 illustrates the effect of berberine on the rat gut microbiota structure; FIG. 1A is the PCoA score plot of changes in the rat gut microbiota structure in response to HFD feeding and berberine administration; FIG. 1B shows the clustering of the gut microbiota based on mahalanobis distances calculated using MANOVA; and FIG. 1C shows the Shannon-Wiener index, calculated after rarefying to an equal number of sequence reads for all samples;

FIG. 2 illustrates some representative differences in the gut microbiota structure caused by berberine treatment using distance triplot of the RDA of gut microbiota;

FIG. 3 illustrates the effect on the short-chain fatty acid contents in rat feces when the rats were fed with high fat diet or normal chow diet; FIG. 3A shows the levels of total short-chain fatty acids (SCFAs); FIG. 3B shows the level of acetic acid; FIG. 3C shows the level of propionic acid; and FIG. 3D shows the level of butyric acid (D);

FIG. 4 illustrates the effect of berberine on obesity phenotypes and food intake in rats; FIG. 4A shows the effect of berberine on the body weight gain; FIG. 4B shows the effect of berberine on the adiposity index, calculated as the fat pad weight (sum of epididymal and perirenal fat pads) per 100 g of total body weight; and FIG. 4C shows the food intake of rats during the entire trial;

FIG. 5 illustrates the effect of berberine on the insulin sensitivity in rats; FIG. 5A shows the effect of berberine on fasting blood glucose (FBG); FIG. 5B shows the effect of berberine on fasting serum insulin (FINS); FIG. 5C shows the effect of berberine onhomeostasis assessment of insulin resistance (HOMA-IR) value, calculated according to the formula fasting insulin (μU/mL)×fasting glucose (mmol/L)/22.5; FIG. 5D shows the effect of berberine onoral glucose tolerance test (OGTT); and FIG. 5E shows the effect of berberine onintra-peritoneal insulin tolerance test (ITT); and

FIG. 6 illustrates the effect of berberine on the level of inflammation factors in rats; FIG. 6A shows the effect of berberine onserum lipopolysaccharide (LPS)-binding protein (LBP); FIG. 6B shows the effect of berberine onserum leptin; FIG. 6C shows the effect of berberine onserum MCP-1; and FIG. 6D shows the effect of berberine onserum adiponectin corrected for body fat.

DETAILED DESCRIPTION

In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, can be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.

This application is generally drawn, inter alia, to compositions, methods, processes, apparatus, systems, devices, and/or products related to improving gut microbiota population.

The application provides novel compositions and methods for improving gut microbiota population. The application identifies bacteria families that are closely related to host metabolism utilizing, for example, high throughput sequencing and multivariate statistical methods.

In one aspect, the application provides methods for improving gut microbiota population. In one embodiment, the method may include selectively enriching a first gut microbiota population. The first gut microbiota population may include, for example, an short-chain fatty acid (SCFA)-producing bacterium. In one embodiment, the method may include suppressing a second gut microbiota population. The second gut microbiota population may include, for example, an endotoxin-producing bacterium.

In one embodiment, the method may include the step of administering to a subject a composition. The composition may be an oral or parenteral formulation. The composition may selectively increase the first gut microbiota population while simultaneously decrease the second gut microbiota population.

The enrichment of the first gut microbiota population and suppression of the second microbiota population may be carried out simultaneously. The method may result in the prevention or treatment of metabolic syndrome including, without limitation, obesity, diabetes mellitus, insulin resistance, hyperlipoproteinemia, hyperuricemia, hepatic steatosis, hypercholesterolemia, hypertriglyceridemia, inflammation, and other disorders.

The short-chain fatty acid (SCFA)-producing bacteria inside gut are mostly beneficial bacteria. These bacteria either directly or, by increasing short-chain fatty acid inside gut, thus indirectly, perform functions including without limitation anti-inflammation, protecting intestinal barrier function, and regulating metabolism and immune system. These functions lead to the prevention or treatment of obesity, insulin resistance, diabetes, and other metabolic diseases.

Using the disclosed methods for improving gut microbiota population, the increased gut microbiota populationmay include Alistipes, Allobaculum, Bacteroides, Barnesiella, Blautia, Butyricicoccus, Butyricimonas, Dorea, Helicobacter, Hespellia, Holdemania, Lawsonia, Oscillibacter, Parabacteroides, Phascolarctobacterium, Prevotella, or Sedimentibacter. In one embodiment, the increased gut microbiota population may include Bacteroidaceae, Coriobacteriaceae, Desulfovibrionaceae, Erysipelotrichaceae, Flavobacteriaceae, Helicobacteracea, IncertaeSedis XI, IncertaeSedis XIV, Lachnospiraceae, Porphyromonadaceae, Prevotellaceae, Rikenellaceae, Ruminococcaceae, or Veillonellaceae; alternatively, the increased gut bacteria may include Campylobacterales, Desulfovibrionales, Bacteroidales, Coriobacteriales, Flavobacteriales, Clostridiales, or Erysipelotrichales; alternatively, the increased gut bacteria may include Epsilonproteobacteria, Deltaproteobacteria, Bacteroidia, Coriobacteridae, Flavobacteria, Clostridia, or Erysipelotrichi; alternatively, the increased gut bacteria may include Proteobacteria, Bacteroidetes, Actinobacteria, or Firmicutes.

For example, the increased gut microbiota population may include a bacterium whose V3 region of 16S rRNA gene sequence has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% similarity with a nucleic acid sequence selected from a group consisting of SEQ ID NO: 1-93.

The endotoxin-producing bacteria inside gut are mostly harmful bacteria, which, either directly or indirectly by increasing endotoxin, promote inflammation, damage intestinal barrier function, and increase disorder in metabolism and immune system, as a result inducing obesity, insulin resistance, diabetes and other metabolic diseases.

According to the methods for improving gut microbiota population disclosed herein, the decreased gut bacteria may include Alistipes, Anaeroplasma, Barnesiella, Bifidobacterium, Butyricimonas, Butyrivibrio, Coprococcus, Fastidiosipila, Helicobacter, Hespellia, Marvinbryantia, Oribacterium, Oscillibacter, Prevotella, Roseburia, Ruminococcus, or TM7_genera_incertae_sedis; alternatively, the decreased gut bacteria may include Helicobacteraceae, Lachnospiraceae, Porphyromonadaceae, Prevotellaceae, Rikenellaceae, Ruminococcaceae, Anaeroplasmataceae, or Bifidobacteriaceae. In one embodiment, the decreased gut microbiota population may include Campylobacterales, Bacteroidales, Clostridiales, Anaeroplasmatales, or Bifidobacteriales; alternatively, the decreased gut bacteria may include Epsilonproteobacteria, Alphaaproteobacteria, Bacteroidia, Clostridia, Actinobacteridae, or Mollicutes. In one embodiment, the decreased gut microbiota population may include Proteobacteria, Bacteroidetes, Actinobacteria, Firmicutes, or Tenericutes.

For example, the decreased gut bacteria may include a bacteria whose V3 region of 16S rRNA gene sequence has at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 98%, or at least about 99% similarity with a nucleic acid sequence selected from a group consisting of SEQ ID NO: 94-268.

The methods may cause decrease of the serum level of pro-inflammatory factors. Example pro-inflammatory factors include without limitation cytokines such as lipopolysaccharide-binding protein, monocyte chemoattractant protein-1, or leptin. Additionally and optionally, the methods may increase the serum level of cytokine such as adiponectin.

The level of gut short-chain fatty acids may be increased using the disclosed methods. The short-chain fatty acids may include without limitation acetic acid, propionic acid, butyric acid, valeric acid, isobutyric acid, and isovaleric acid.

To improve the gut microbiota population, the compositions may be administered orally or parentally. In one embodiment, the composition may be a food, a drink, a supplement, or a pharmaceutical formulation. In one embodiment, the composition may be in the form of suppository, tablet, pill, granule, powder, film, microcapsule, aerosol, spirit, tincture, tonic, liquid suspension, or syrup. The composition may be administered at a dosage of from about 50 mg/kg body weight to about 400 mg/body weight.

In one example, the composition including berberine was administered to a subject. The gut microbiota population of the subject was then analyzed using 454 pyrosequencing techniques and the level of short-chain fatty acid was assayed by gas chromatography. The results demonstrated that berberine is capable of altering gut microbiota population: enriching certain bacteria including those that produce short-chain fatty acid while simultaneously suppressing or eliminating certain bacteria including those that produce endotoxin. It is further demonstrated that berberine administered orally is capable of increasing the level of shot-chain fatty acid inside the gut, and the increase is more pronounced in individuals who have metabolic syndrome. Additional experimentation and observation further demonstrated that above described effects by berberine on the gut microbiota population have beneficial results including without limitation improving insulin sensitivity, reducing inflammation, controlling weight gain, and preventing obesity induced by over-eating, chronic inflammation and insulin resistance.

In another aspect, the application provides methods for screening drugs, compounds, compositions, extracts, or formulations capable of improving gut microbiota population. The methods may be used in the development of drugs, nutritional supplements, health care products, food, and beverages that improve health and/or prevent obesity or other related metabolic syndromes by targeting gut microbiota population in a subject.

In one embodiment, the screening method may include administering to a control subject an effective amount of a control composition to increase the first gut microbiota population while simultaneously decrease the second gut microbiota population in the control subject, administering to a test subject an amount of a test composition, and comparing the gut microbiota population of the controlled subject and the gut microbiota population of the test subject.

As used herein, the term “subject” refers to an animal, such as a mammal, for example a human. In some embodiments, the subject may be a rat. In some embodiments, the subject may be a mouse. In some embodiments, the subject may be a human.

If the test compound demonstrates similar effect on gut microbiota as the control, the test compound is active in improving gut microbiota population. As used therein, “similar” refers to a similarity of at least about 75%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, or at least about 99%.

The test composition may be a single compound, a mixture, a food, a food additive, a nutritional supplement, health care product, a pharmaceutical formulation, or a beverage.

In a further aspect, the application provides compositions for improving gut microbiota population. In one embodiment, the composition may be capable of selectively increasing the first gut microbiota population while simultaneously decreasing the second gut microbiota population in a subject.

The composition may include a chemical compound, a natural medicine, a natural product, or an herbal extract. In one embodiment, the chemical compound may include, without limitation, berberine, berberine derivatives, isoquinoline alkaloids, or any combinations thereof.

In one embodiment, the composition may include natural medicine, whole, fragmented or powdered herb, or herbal extract derived from plants of Berberis, Coptis, Scutellaria, Phellodendron, Momordica, Ilex, Sophora, Gentiana, Anemarrhena, Gardenia, Rheum, or Taraxacum. In one embodiment, the composition may include natural medicine, whole, fragmented or powdered herb, or herbal extract derived from plants of Berberidaceae, Ranunculaceae, Lamiaceae, Rutaceae, Cucurbitacea, Aquifoliaceae, Leguminosae, Gentianaceae, Agavaceae, Rubiaceae, Polygonaceae, Asteraceae, Menispermaceae, or Cucurbitaceae. In one embodiment, the composition may include natural medicine, whole, fragmented or powdered herb, or herbal extract derived from Berberis vulgaris, Coptischinensis, Scutellariabaicalensis, PhellodendriChinensis, Momordicacharantia, Ilex kudingcha, Sophoraflavescens, Gentianascabra, Anemarrhenaasphodeloides, Gardenia jasminoides, Rheum palmatum, or Herba Taraxaci.

The following examples are for illustration of the execution and property of representative method of the application. These examples are not intended to limit the scope of the application.

EXAMPLES

These examples use Wistar rats (8 weeks old, male) as testing subjects and berberine as a representative compound. 40 Wistar rats were acclimatized for two weeks and were subsequently randomly divided into four groups: normal diet group (NCD), normal diet plus berberine treatment (NCD+BBR), high fat diet (HFD), and high fat diet plus berberine treatment (HFD+BBR). Each group continued for another 18 weeks. During these 18 weeks, the NCD+BBR group received intragastric administration of berberine at stated levels. Feces samples from each animal were collected at various time points. 454 pyrosequencing was performed to analyze gut microbiota structure. Gas chromatography was used to assay the short-chain fatty acid level of the feces. In addition, weight, food intake, insulin sensitivity, systemic inflammation levels were monitored and measured during the 18-week period.

Berberine Altered the Gut Microbiota Population Under Both Normal Diet and High Fat Diet Conditions

The gut microbiota populations in rats from all four experimental groups were analyzed by 454 pyrosequencing and multivariate statistical analyses. PCoA analysis based on unweighted Unifrac distance demonstrated that berberine altered gut microbiota structure in both the normal diet group and high fat diet group at a statistically significant level; and berberine accounts for 12.6% of overall changes in the gut microbiota population (FIG. 1A). Diet also exerted statistically significant influence on gut microbiota population. FIG. 1A reveals a statistically significant difference (3.7%) in gut microbiota population between two different diets (NCD versus HFD) along the vertical axis. The multivariate variance analysis (MANOVA) on the four groups demonstrated that berberine or diet has a statistically significant influence on the gut microbiota (P<0.01), but the most pronounced difference derives from the presence of berberine (FIG. 1B). Shannon-Wiener parameter indicates that berberine reduces diversity of gut microbiota population at a statistically significant level (P<0.05).

Berberine Enriches the Short-Chain Fatty Acid-Producing Bacteria and Reduces Endotoxin-Producing Bacteria in Gut Microbiota Population

268 berberine-related OTU were identified by redundancy analysis (RDA) and the detailed results are shown in FIG. 2, TABLE 1, and TABLE 2. 93 OTU (SEQ_ID_NO 1-93) (TABLE 1) are enriched by berberine, while 175 OTU (SEQ_ID_NO 94-268) (TABLE 2) were suppressed or eliminated.

The taxonomy of these 268 OTU was analyzed using RDP classifier with representative sequence of the OTU. It was revealed that the berberine-suppressed bacteria included those of Alistipes, Anaeroplasma, Barnesiella, Bifidobacterium, Butyricimonas, Butyrivibrio, Coprococcus, Fastidiosipila, Helicobacter, Hespellia, Marvinbryantia, Oribacterium, Oscillibacter, Prevotella, Roseburia, Ruminococcus, TM7_genera_incertae_sedis, and others. Among them, the Helicobacter, belonging to Proteobacteria phylum, is capable of producing highly active endotoxin. In addition, it was revealed that the berberine-increased bacteria included those of Alistipes, Allobaculum, Bacteroides, Barnesiella, Blautia, Butyricicoccus, Butyricimonas, Dorea, Helicobacter, Hespellia, Holdemania, Lawsonia, Oscillibacter, Parabacteroides, Phascolarctobacterium, Prevotella, and Sedimentibacter. Among them, Blautia, Allobaculum, Prevotella, Bacteroides, and Butyricimonas are relatively abundant and are capable of producing short-chain fatty acid.

Therefore, when administered to a subject, berberine is capable of enriching the short-chain fatty acid-producing bacteria and reducing endotoxin-producing bacteria in gut microbiota population.

Berberine Increases Gut Short-Chain Fatty Acid Level in Rats Fed Normal Diet or High Fat Diet

The levels of short-chain fatty acid (including acetic acid, propionic acid, butyric acid, valeric acid, isobutyric acid, isovaleric acid, etc.) in rat feces were assayed by gas chromatography. The result demonstrated that oral administration of 100 mg/kg body weight may increase the level of gut short-chain fatty acid in rats fed with normal diet or high fat diet. The effect on the levels of acetic acid and propionic acid are especially pronounced (FIG. 3). Therefore, berberine is capable of increasing gut short-chain fatty acid level in rats fed normal diet or high fat diet.

Berberine Reduces Obesity Phenotype of Rats

The body weight of all four groups of rats were monitored during the duration of the experiments and analyzed. The results demonstrated that, after 18 weeks of high fat diet, the HFD group has significantly higher body weight than the normal diet group (P<0.01); intragastric administration of berberine at the dosage of 100 mg/kg effectively limits rat body weight growth, especially for rats fed high fat diet. The result is especially surprising that during the entire experimental process, the body weight of the HFD+BBR group is limited to a level similar to that of normal diet group, displaying no statistically significant difference (P>0.05). Berberine also influences, to a certain degree, the body weight of rats fed a normal diet (FIG. 4).

At the end of experiment, animals were euthanized. Fasting body weight, epididymal fat weight, and perirenal fat weight were measured. Adiposity index ([epididymal fat weight+perirenal fat]/fasting weight×100) is shown in FIG. 4B. After 18 weeks of high fat diet, the adiposity index of the HFD group is significantly higher than that of NCD, and berberine treatment significantly reduces adiposity index. Moreover, neither high fat diet nor berberine had significant effect on liver and pancreas, indicating surprisingly that long term use of berberine has no obvious side effect to rat's normal physiological function. Results of the calorie intake of these rats demonstrated that oral administration of berberine at 100 mg/kg body weight has a significant inhibitory effect on rat food intake, especially on rats fed a high fat diet (FIG. 4C).

Berberine Reduces Insulin sensitivity in Rats Fed a Normal Diet or High Fat Diet

The fasting blood glucose (FBG) and fasting insulin in serum (FINS) were measured for all four experimental groups of rats. Rats fed a HFD for 18 months had a significant higher level of FBG than that of NCD. Surprisingly, berberine effectively reduced FBG in NCD and HFD rats, especially in HFD rats where the FBG reduction was significant (P<0.05) (FIG. 5A). The result of berberine effect on insulin level is shown in FIG. 5B. The FINS of rat fed a HFD was significantly higher than that of NCD group; however, after 18 month of berberine intervention at the level of 100 mg/kg body weight, FINS level was significantly reduced even in rats fed a HFD (HFD+BBR), to reach a level comparable to that of normal diet. FIG. 5C shows the result of HOMA insulin resistance index to evaluate the insulin resistance status in rats, which demonstrates that after 18 weeks of HFD induction, rats formed apparent insulin resistance; yet berberine intervention at 100 mg/kg body weight prevented the formation of insulin resistance (P<0.05).

In order to further examine insulin sensitivity, oral glucose tolerance test and intraperitoneal injection of insulin tolerance test were conducted, and the results are shown in FIG. 5D, and 5E, respectively. Consistent with the FBG and FINS result, after 18 weeks of high fat diet inducement, oral glucose tolerance and intraperitoneal injection of insulin tolerance were significantly damaged, meanwhile, berberine intervention at 100 mg/kg body weight significantly prevented the loss of glucose tolerance and insulin tolerance, demonstrating the berberine may play an important role in improving glucosemetabolism.

Berberine Reduces Systemic inflammation Level in Rats Fed a High Fat Diet

In order to evaluate the systemic inflammation levels of all four experimental groups of rats, the serum levels of lipopolysaccharide (LPS)-binding protein (LBP), monocyte chemoattractant protein-1 (MCP-1), leptin, and adiponectin were measured, and results are shown in FIG. 6. The experiments demonstrates that HFD significantly increased LBP level in serum; but administering berberine at 100 mg/kg significantly abrogated the increase of serum LBP (P<0.05, FIG. 6A).

MCP-1 is a pro-inflammatory cytokine that functions in chemotaxis and activation of monocytes/macrophages. Occurrence and development of many inflammation-related diseases are closely related to MCP-1, including atherosclerosis, obesity, type 2 diabetes, arthritis, sepsis, and chronic bacterial infection. The results from the experiment demonstrated that, in the process of the gradual onset of obesity and insulin resistance in rat induced by HFD, MCP-1 level is gradually elevated; however, after intervention with berberine administering, MCP-1 level was significantly reduced, and, surprisingly, was even lower than that of NCD group (FIG. 6B).

Leptin is a hormone secreted by adipose tissue, and broadly participates in lipid, glucose, and energy metabolism. The results from the experiment demonstrated that serum leptin level in HFD group is significantly higher than that of NCD group (P<0.01); however, berberine significantly reduced the serum leptin level in rat, especially in rats fed a HFD (P<0.05, FIG. 6C).

The adiponectin levels in all four groups were analyzed. The results show that the adiponectin level normalized against body fat weight, was significantly lower in HFD group when compared to that of NCD group (P<0.001); however, berberine administration significantly increased adiponectin level in rats fed a HFD (P<0.01, FIG. 6D). Therefore, berberine improves gut microbiota population, reduces LPB, MCP-1, and lpetin level, and increases adiponectin secretion. TABLE 1 16S rRNA gene V3 region sequence of those bacteria enriched by berberine.

List	OTUName	16S rRNA Gene V3 Region Sequence
SEQ_ID_NO_	R_U00449939	TAGGGAATATTGCTCAATGGGGGAAACCCTGAAGCA
1		GCAACGCCGCGTGGAGGATGAAGGTTTTCGGATTGT
		AAACTCCTTTTCTAAGAGAAGATTATGACGGTATCTT
		AGGAATAAGCACCGGCTAACTCCGTGCC
SEQ_ID_NO_	R_U01131573	GGGGAAACCCTGAAGCAGCAACGCCGCGTGGAGGAT
2		GAAGGTTTCGGATTGTAAACTCCTTTCTAAGAGAAGA
		TTATGACGGTATCTTAGGAATAAGCACCGGCTAACTC
		CGTGCC
SEQ_ID_NO_	R_U00442991	TGGGGAATATTGCGCAATGGGCGAAAGCCTGACGCA
3		GCGACGCCGCGTGAGGGATGAAGGTCCTCGGATCGT
		AAACCTCTGTCAGGGGGGAAGAAGCGCCTGTGAGCA
		AATAGTTCATGGGTTTGACGGTACCCCCAAAGGAAG
		CACCGGCTAACTCCGTGCC
SEQ_ID_NO_	R_U01131468	TGAGGAATATTGGTCAATGGGCGCAGGCCTGAACCA
4		GCCAAGTAGCGTGAAGGATGACTGCCCTATGGGTTGT
		AAACTTCTTTTATATGGGAATAAAGTTTTCCACGTGT
		GGAATTTTGTATGTGCCATATGAATAAGGATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00000076	TGAGGAATATTGGTCAATGGACGAGAGTCTGAACCA
5		GCCAAGTAGCGTGAAGGATGACTGCCCTATGGGTTGT
		AAACTTCTTTTATATGGGAATAAAGTGAGCCACGTGT
		GGCTTTTTGTATGTACCATACGAATAAGGATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00000261	TGAGGAATATTGGTCAATGGGCGCAGGCCTGAACCA
6		GCCAAGTAGCGTGAAGGATGACTGCCCTATGGGTTGT
		AAACTTCTTTTATATGGGAATAAAGTTTTCCACGTGT
		GGAATTTTGTATGTACCATATGAATAAGGATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00277049	TGAGGAATATTGGTCAATGGGCGCAGGCCTGAACCA
7		GCCAAGTAGCGTGAAGGATGACTGCCCTATGGGTTGT
		AAACTTCTTTTATATGGGAATAAAGTTTTCCTACGTG
		TGGAATTTTGTTATGTACCATATGAATAAGGATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U01140154	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCA
8		GCCAAGTAGCGTGCAGGACGACGGCCCTATGGGTTG
		TAAACTGTCTTTTATACGGGGATAAAGTATGCCACGT
		GTGGTTTATTGCAGGTACCGTATGAATAAGGACCGGC
		TAATTCCGTGCC
SEQ_ID_NO_	R_U00797917	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCA
9		GCCAAGTAGCGTGCAGGACGACGGCCCTATGGGTTG
		TAAACTGCTTTTATACGGGGATAAAGTATGCCACGTG
		TGGTTTATTGCAGGTACCGTATGAATAAGGACCGGCT
		AATTCCGTGCC
SEQ_ID_NO_	R_U01135802	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
10		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGCCGGGGAGGCAATGCCCACGCTCG
		CGAGCTGGGAAGGAGAGTACCCGGAGAAAAAGACAT
		CGGCTAACTCCGTGCC
SEQ_ID_NO_	R_U01199632	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
11		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGCCGGGGAGCAATGCCCACGCTCGC
		GAGCTGGGAAGGAGAGTACCCGGAGAAAAAGACATC
		GGCTAACTCCGTGCC
SEQ_ID_NO_	R_U01136954	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
12		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGCCGGGGAGCAAATGCCCAGCTCGC
		GAGCTGGGAAGGAGAGTACCCGGAGAAAAAGCATCG
		GCTAAACTCCGTGCC
SEQ_ID_NO_	R_U01156163	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCA
13		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGTCAGGGAGCAAGAACAGGCACGT
		GTGCCTGACTGAGAGTACCTGAAGAAAAAGACATCG
		GCTAACTCCGTGCC
SEQ_ID_NO_	R_U00436427	TGAGGAATATTGGTCAATGGCCGGAAGGCTGAACCA
14		GCCAAGTCGCGTGAGGGACTAAGGCCCTACGGGTCG
		TAAACCTCTTTTGCCGGGGAGCAATGGGGCCCTTGCG
		AGGGCCCAGGGAGAGTACCCGGAGAAAAAGCATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U01161731	TGAGGAATATTGGTCAATGGCCGGGAGGCTGAACCA
15		GCCAAGTCGCGTGAGGGATGACGGCCCTACGGGTTG
		TAAACCTCTTTTGTCGGGGAGCAAAGGACTTCACGAG
		TGGAGTTTCGAGAGTACCCGAAGAAAAAGACATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U00804243	TGAGGAATATTGGTCAATGGCCGGGAGGCTGAACCA
16		GCCAAGTCGCGTGAGGGATGACGGCCCTACGGGTTG
		TAAACCTCTTTTGTCGGGGAGCAAAGGACTTCACGAG
		TGGAGTTTCGAGAGTACCCGAAGAAAAAGCATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U00832647	TGAGGAATATTGGTCAATGGCCGGGAGGCTGAACCA
17		GCCAAGTCGCGTGAGGGATGACGGCCCTACGGGTTG
		TAAACCTCTTTGTCGGGGAGCAAAGGACTTCACGAGT
		GGAGTTTCGAGAGTACCCGAAGAAAGACATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00013412	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCA
18		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGTCAGGGAGCAAGAACAGGCACGT
		GTGCCTGACTGAGAGTACCTGAAGAAAAAGCATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U00807079	TGAGGAATATTGGTCAATGGCCGAGAGGCTGAACCA
19		GCCAAGTCGCGTGAGGGATGACGGCCCTACGGGTTG
		TAAACCTCTTTTGTCGGGGAGCAAAGGACTTCACGTG
		TGAAGTTTCGAGAGTACCCGAAGAAAAAGCATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U00005346	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
20		GCCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTG
		TAAACCTCTTTTGCCGGGGAGCAATGCCGCTCTTGCG
		AGAGCGGAGGGAGAGTACCCGGAGAAAAAGCATCG
		GCTAACTCCGTGCC
SEQ_ID_NO_	R_U00004086	TGAGGAATATTGGTCAATGGCCGGAAGGCTGAACCA
21		GCCAAGTCGCGTGAGGGAATAAGGCCCTACGGGTCG
		TAAACCTCTTTTGTCAGGGAGCAAAGCTGGCTACGCG
		TAGCCAGAAGGAGAGTACCTGAAGAAAAAGCATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U01130438	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
22		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTGCCGGGAGCAATGCCCAGCTCGCGAG
		CTGGGAAGGAGAGTACCCGGAGAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U01131459	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
23		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTGCCGGGGAGCAATGCCCAGCTCGCGA
		GCTGGGAAGGAGAGTACCCGGAGAAAAGACATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U00436448	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
24		GCCAAGTCGCGTGAGGGACTAAGGCCCTACGGGTCG
		TAAACCTCTTTTGCCGGGGAGCAAGCCGTCCCACGTG
		TGGGCCGGTGGAGAGTACCCGGAGAAAAAGCATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U00474862	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
25		GCCAAGTCGCGTGAGGGACTAAGGCCCTACGGGTCG
		TAAACCTCTTTTGCCGGGGAGCAAGCCGTCCCACGTG
		TGGGCCGGTGGAGAGTACCCGGAGAAAAAGACATCG
		GCTAACTCCGTGCC
SEQ_ID_NO_	R_U00001388	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
26		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTGCCGGGGAGCAATGCCCAGCTCGCG
		AGCTGGGAAGGAGAGTACCCGGAGAAAAAGCATCGG
		CTAACTCCGTGCC
SEQ_ID_NO_	R_U01185184	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCA
27		GCCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTG
		TAAACCTCTTTTTGCCGGGGGAGCAATGCCCAGCTCG
		CGAGCTGGGAAGGAGAGTACCCGGAGAAAAAAGCAT
		CGGCTAACTCCGTGCC
SEQ_ID_NO_	R_U00000528	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCA
28		GCCAAGTCGCGTGAAGGATGAAGGATCTATGGTTTGT
		AAACTTCTTTTATATGGGAATAAAGTGAGGAACGTGT
		TCCTTTTTGTATGTACCATATGAATAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00000002	TGAGGAATATTGGTCAATGGACGAGAGTCTGAACCA
29		GCCAAGTAGCGTGAAGGATGACTGCCCTATGGGTTGT
		AAACTTCTTTTATACGGGAATAAAGTGAGGCACGTGT
		GCCTTTTTGTATGTACCGTATGAATAAGGATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U00147566	TGAGGAATATTGGTCAATGGACGCAAGTCTGAACCA
30		GCCATGCCGCGTGCAGGAAGACGGCTCTATGAGTTGT
		AAACTGTCTTTTGTACTAGGGTAAACGCTCTTACGTG
		TAGGAGCCTGAAAGTATAGTACGAATAAGGATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U00000394	TGAGGAATATTGGTCAATGGACGCAAGTCTGAACCA
31		GCCATGCCGCGTGCAGGAAGACGGCTCTATGAGTTGT
		AAACTGCTTTTGTACTAGGGTAAACGCTTCTACGTGT
		AGGAGCCTGAAAGTATAGTACGAATAAGGATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U00047397	TGGGGAATTTTGCGCAATGGGGGGAACCCTGACGCA
32		GCAACGCCGCGTGCGGGATGACGGCCCTCGGGTTGT
		AAACCGCTTTCAGCAGGGAAGACCACGACGGTACCT
		GCAGAAGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000552	TGAGGAATATTGGGCAATGGGCGGAAGCCTGACCCA
33		GCCATGCCGCGTGCAGGAAGACAGCCCTATGGGTCG
		TAAACTGCTTTTTTAGAGGAAGAATAAAGTCTACGTG
		TAGACCGATGACGGTACTTTAAGAAAAAGCATCGGC
		TAACTCCGTGCC
SEQ_ID-NO_	R_U00441706	GTAGGGAATATTGCACAATGGGGGAAACCCTGATGC
34		AGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATG
		TAAACTTCTATCAGCAGGGAAGACAATGACGGTACC
		TGACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00119974	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
35		GCGACGCCGCGTGAAGGAAGAAGTATTTCGGTATGT
		AAACTTCTATCAGCAGGGAAGAAAGTGACAGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00104206	TGGGGAATATTGCACAATGGGGGAAACCCGTACGAT
36		GCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTA
		TGTAAACTTCTATCAGCAGGGAAGATAATGACGGTA
		CCTGACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00580795	TGGGGAATATTGCACAATGGGGGAAACCCGTACGAT
37		GCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTA
		TGTAAACTTACTATCAGCAGGGAAGATAATGACGGT
		ACCTGACTAAGAAGCCCCGGCCTAACTACGTGCC
SEQ_ID_NO_	R_U01129900	AAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAG
38		TATCTCGGTATGTAAACTTCTATCAGCAGGGAAGACA
		ATGACGGTACCTGACTAAGAACGCCCGGCTAACTAC
		GTGCC
SEQ_ID_NO_	R_U00016467	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
39		GCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGT
		AAACTTCTATCAGCAGGGAAGATAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAATTACGTGCC
SEQ_ID_NO_	R_U00000367	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
40		GCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGT
		AAACTTCTATCAGCAGGGAAGATAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00459481	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
41		GCAACGCCGCGTGGGTGAAGGAGCGTTTCGGCGCGT
		AAAGCCCTGTCAGCGGGGAAGAAAAAAGACGGTACC
		CGACCAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000215	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCA
42		GCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGT
		AAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00071963	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
43		GCGACGCCGCGTGAAAGATGAAGTATTTCGGTATGT
		AAACTTCTATCAGCAGGGAAGAAAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000939	TGGGGAATATTGCACAATGGAGGAAACTCTGATGCA
44		GCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGT
		AAAGCTCTATCAGCAGGGAAGACAGTGACGGTACCT
		GACTAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U00472681	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCA
45		GCGACGCCGCGTGAGTGACGAAGTATCTCGGTATGT
		AAAGCTCTGTCAGCAGGGAAGAAGAATGACGGTACC
		TGAAGAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U00000105	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCA
46		GCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGT
		AAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000279	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCA
47		GCAACGCCGCGTGAAGGAAGACGGTTTTCGGATTGT
		AAACTTCTATCAATAGGGAAGAAAGAAATGACGGTA
		CCTAAATAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00022935	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
48		GCAACGCCGCGTGAAGGAAGACGGTTTTCGGATTGT
		AAACTTCTATCAATAGGGAAGAAAGAAATGACGGTA
		CCTAAATAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000550	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
49		GCGACGCCGCGTGGAGGAAGAAGGTCTTCGGATTGT
		AAACTCCTGTCCCAGGGGACGATAATGACGGTACCCT
		GGGAGGAAGCACCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00009280	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCA
50		GCAACGCCGCGTGAAGGAAGACGGTTTTCGGATTGT
		AAACTTCTGTTCTTAGTGAAGAAGAATGACGGTAGCT
		AAGGAGCAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00164237	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCA
51		GCAACGCCGCGTGAAGGAAGACGGTTTTCGGATTGT
		AAACTTCTGTTCTTAGTGAAGAATAATGACGGTAACT
		AAGGAGCAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00032911	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
52		GCGACGCCGAGTGAGGGAAGAAGGTTTTCGGATTGT
		AAACCTCTGTCCTTGGTGAAGATAATGACGGTAGCCA
		AGGAGGAAGCTACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00040533	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCA
53		GCGACGCCGCGTGAGGGAAGACGGCCTTCGGGTTGT
		AAACCTCTGTCGCAGGGGACGAAGGAAGTGACGGTA
		CCCTGTGAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01145869	GAATATTGCGCAATGGGGGCAACCCTGACGCAGCAA
54		CGCCGCGTGAAGGATGAAGGTTTTCGGATTGTAAACT
		TCTTTTATCAAGGACGAAGGACGTGACGGTACTTGAT
		GAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00211687	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
55		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTACCAGGGGACGAAGGACGTGACGGT
		ACCTGGAGAAAAAGCAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01206474	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
56		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTACCTAGGGACGAAGGACGTGACGGTA
		CCTGGAGAAAAAGACAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01219720	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
57		GCAACGCCGCGTGAAGGAAGAAGGTTTTCGGGTTGT
		AAACTTCTTTTACCAGGGACGAAGGACGTGACGGTA
		CCTGGAGAAAAAGCAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01210669	GACCCAGCAACGCCGCGTGAAGGAAGAAGGTCGTTT
58		CGGGTTAGTAAACTTCTTTTACCGAGGGACGAAGGAC
		GTGACGGTACCTGGAGAAAAAGCAACGGCTAACTAC
		GTGCC
SEQ_ID_NO_	R_U00001394	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
59		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTACCAGGGACGAAGGACGTGACGGTA
		CCTGGAGAAAAAGCAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00460521	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
60		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTACCTAGGGACGAAGGACGTGACGGTA
		CCTGGAGAAAAAGACAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00831992	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
61		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTACCAGGGACGAAGGACGTGACGGTA
		CCTGGAGAAAAGACAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01143501	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCA
62		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTCTGGGGGACGAAGAAAGTGACGGTA
		CCCCACGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00815791	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCA
63		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTCTGGGGGGCGAAGAAAGTGACGGTA
		CCCCAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00043629	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCA
64		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTCTGGGGGACGAAGAAAGTGACGGTA
		CCCCAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00164098	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCA
65		GCAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGT
		AAACTTCTTTTCTCGGGGACGAACAAATGACGGTACC
		CGAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000374	TGGGGAATATTGCGCAATGGGGGCAACCCTGACGCA
66		GCAACGCCGCGTGATTGAAGAAGGTCTTCGGATTGTA
		AAAATCTTTTATCAAGGACGAAGAAGTGACGGTACTT
		GATGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00003296	TGGGGAATATTGGGCAATGGGGGGAACCCTGACCCA
67		GCAACGCCGCGTGAGGGAAGAAGGTTTTCGGATCGT
		AAACCTCTGTCCTTGGTGAAGAGGAGAAGACGGTAG
		CCAAGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00027329	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCA
68		GCAACGCCGCGTGAGGGAAGAAGGTTTTCGGATCGT
		AAACCTCTGTCCTTGGTGAAGAGAAGAAGACGGTAG
		CCAAGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00003420	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCA
69		GCAACGCCGCGTGAAGGATGAAGTATTTCGGTATGT
		AAACTTCTATCAGCAGGGAAGATAACGACGGTACCT
		GACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00436238	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCA
70		GCAACGCCGCGTGAACGAAGAAGGTCTTCGGATTGT
		AAAGTTCTGTCCTTAGGGAAGAAGAAAGTGACGGTA
		CCTAAGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00439751	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCA
71		GCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGT
		AAAGCTCTATCAGCAGGGAAGAAAATGACGGTACCT
		G
SEQ_ID_NO_	R_U00004741	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCA
72		GCGACGCCGCGTGAAGGAAGAAGTATTTCGGTATGT
		AAACTTCTATCAGCAGGGAAGAAAATGACGGTACCT
		GACTAAGAAGCCCCGGCTAATTACGTGCC
SEQ_ID_NO_	R_U01160251	TAGGGAATTTTTCGTCAATGGGCGCAAGCCTGAACGA
73		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAGGAAGGGAAGAG
		GAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01166410	TAGGGAATTTTTCGTCAATGGGCGCAAGCCTGAACGA
74		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAGGAAGGAAAGAG
		GAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01169117	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
75		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAAACTCTGTTGCGGGGGAAAAAAGGAAGGGAAG
		AGGAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAA
		GTCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01180557	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
76		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTTGCGGGGGGAAAAAGGAAGGGAAGA
		GGAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAG
		TCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00804007	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
77		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAGGAAGGGAAGAG
		GAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01143008	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
78		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGAAAAGGAAGGGAAGAGGA
		AATGCTTTTCTTTTGTATGGTACCCCGCCAGAAAGTC
		ACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01145549	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
79		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAGGAAGGGAAGAGG
		AAATGCTTTTCTTTTGTATGGTACCCCGCCAGAAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00808391	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
80		GCAATGCCGCGTGGGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAGGAAGGGAAGAGG
		AAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGTC
		ACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01144224	GGTAATTTTCGTCAATGGGCGCAAGCCTGAACGAGC
81		AATGCCGCGTGGGCGAAGAAGGTCTTCGGATACGTA
		AACTCTGTTGCGGGGGAAAAAGGAAGGGAAGAGGA
		AATGCTTTCTTTTGATGGTACCCCGCCAGAAAGTCAC
		GGCTAACTACGTGCC
SEQ_ID_NO_	R_U01214804	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
82		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAGGAAGGGAAGAG
		GAAATGCTTTTCTTTTGATGGTACCCCGCCCAGAAAG
		TCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01173110	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
83		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAAGGAAGGGAAGA
		GGAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAG
		TCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00305232	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
84		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAAGGAAGGGAAGAG
		GAAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00043735	TAGGGAATTTTTCGTCAATGGGCGCAAGCCTGAACGA
85		GCAATGCCGCGTGAACGAGGAAGGTCTTCGGATCGT
		AAAGTTCTGTTGAGAGGGAAAAAGGGTCACCAGAGG
		AAATGCTGGTGAAGTGATATTACCTTTCGAGGAAGTC
		ACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000409	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
86		GCAATGCCGCGTGAACGAGGAAGGTCTTCGGATCGT
		AAAGTTCTGTTGAGAGGGAAAAAGGGTCACCAGAGG
		AAATGCTGGTGAAGTGATATTACCTTTCGAGGAAGTC
		ACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00029718	GGTAATTTTCGTCAATGGGCGCAAGCCTGAACGAGC
87		AATGCCGCGTGAACGAGGAAGGTCTTCGGATCGTAA
		AGTTCTGTTGAGAGGGAAAAAGGGTCACCAGAGGAA
		ATGCTGGTGAAGTGATATTACCTTTCGAGGAAGTCAC
		GGCTAACTACGTGCC
SEQ_ID_NO_	R_U00007185	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
88		GCAATGCCGCGTGAACGAGGAAGGTCTTCGGATCGT
		AAAGTTCTGTTGAGAGGGAAAAAAGGGTCACCAGAG
		GAAATGCTGGTGAAGTGATATTACCTTTCGAGGAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00011248	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
89		GCAATGCCGCGTGAACGAGGAAGGTCTTCGGATCGT
		AAAGTTCTGTTGAGAGGGAAAAGGGTCACCAGAGGA
		AATGCTGGTGAAGTGATATTACCTTTCGAGGAAGTCA
		CGGCTAACTACGTGCC
SEQ_ID_NO_	R_U01156257	TAGGGAATTTTCGTCAAGTGGGCGCAAGCCTGAACG
90		AGCAATGCCGCGTGAACGAGGAAGGTCTTCGGATAC
		GTAAAGTTCTGTTGAGAGGAAAAAGGGTCACCAGAG
		GAAATGCTGGTGAAGTGATATTACCTTTCGAGGAAGT
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00808203	TAGGGAATTTTCGTCAATGGGCGCAAGCCTGAACGA
91		GCAATGCCGCGTGAGCGAAGAAGGTCTTCGGATCGT
		AAAACTCTGTTGCGGGGGAAAAGGAAGGGAAGAGG
		AAATGCTTTTCTTTTGATGGTACCCCGCCAGAAAGTC
		ACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00003073	TAGGGAATTTTCGGCAATGGGCGAAAGCCTGACCGA
92		GCAACGCCGCGTGAGTGAAGAAGGCCTTCGGGTTGT
		AAAGCTCTGTTGTGAAGGAAGAACGGCTCATAGAGG
		GAATGCTATGGGAGTGACGGTACTTTACCAGAAAGC
		CACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U00000235	TGGGGAATCTTCCGCAATGGACGAAAGTCTGACGGA
93		GCAACGCCGCGTGAGTGATGAAGGATTTCGGTCTGTA
		AAGCTCTGTTGTTTATGACGAACGTGCAGTGTGTGAA
		CAATGCATTGCAATGACGGTAGTAAACGAGGAAGCC
		ACGGCTAACTACGTGCC

TABLE 2
16S rRNA gene V3 region sequence of those bacteria
suppressed/eliminated by berberine.
List	OTUName	16S rRNA Gene V3 Region Sequence
SEQ_ID_NO_	R_U0043619	TGAGGAATATTGGGCAATGGGGGCAACCCTGACCCAG
94	5	CCATGCCGCGTGAGTGAAGAAGGTTTTCGGATTGTAA
		AGCTCTTTCGGATGTGACGATGATGACGGTAGCATCT
		AAAGAAGCCCCGGCAAACTTCGTGCC
SEQ_ID_NO_	R_U0010141	GNGGGAAACCCTGAAGCAGCAACGCCGCGTGGAGGA
95	6	TGAAGGTTTCGGATTGTAAACTCCTTTGTTAGAGAAG
		ATAATGACGGTATCTAACGAATAAGCACCGGCTAACT
		CCGTGCC
SEQ_ID_NO_	R_U0000040	TAGGGAATATTGCTCAATGGGGGAAACCCTGAAGCAG
96	7	CAACGCCGCGTGGAGGATGAAGGTTTTCGGATTGTAA
		ACTCCTTTTGTTAGAGAAGATAATGACGGTATCTAAC
		GAATAAGCACCGGCTAACTCCGTGCC
SEQ_ID_NO_	R_U0080096	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
97	6	CCAAGTAGCGTGCAGGAAGACGGCCCTACGGGTTGTA
		AACTGCTTTTATGCGGGGATAAAGTGCAATACGTGTA
		TTGCTTTGCAGGTACCGCATGAATAAGGACCGGCTAA
		TTCCGTGCC
SEQ_ID_NO_	R_U0113198	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
98	2	CCAAGTAGCGTGCAGGATGACGGCCCTACGGGTTGTA
		AACTGCTTTTTTGCGGGAATAAAGCGGCTCACGTGTG
		AGCCTTTGCATGTACCGCACGAATAAGGACCGGCTAA
		TTCCGTGCC
SEQ_ID_NO_	R_U0079783	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
99	9	CCAAGTAGCGTGCAGGATGACGGCCCTATGGGTTGTA
		AACTGCTTTTATACGGGGATAAAGTTGGGGACGTGTC
		CCCATTTGTAGGTACCGTATGAATAAGGACCGGCTAA
		TTCCGTGCC
SEQ_ID_NO_	R_U0000398	TGAGGAATATTGGTCAATGGTCGTGAGACTGAACCAG
100	1	CCAAGTAGCGTGCGGGATGAAGGCCCTCCGGGTCGTA
		AACCGCTTTTAGACGGGGATAAAAGGGCATACGTGTA
		TGCCGTATTGCATGTACCGTCAGAAAAAGGACCGGCT
		AATTCCGTGCC
SEQ_ID_NO_	R_U0000140	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
101	4	CCAAGTAGCGTGAAGGAAGACTGCCCTATGGGTTGTA
		AACTTCTTTTATAAGGGAATAAAGAGCGCCACGTGTG
		GTGTGTTGTATGTACCTTATGAATAAGCATCGGCTAAT
		TCCGTGCC
SEQ_ID_NO_	R_U0000005	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
102	2	CCAAGCCGCGTGAGGGAAGAAGGCGCCAGGCGTCGT
		AAACCTCTTTTGCCGGGGAACAAAGGGCGCCACGTGT
		GGCGTTGTGAGTGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000096	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
103	4	CCAAGCCGCGTGAGGGAGGAAGGCGCCAGGCGTCGT
		AAACCTCTTTTGCCGGGGAACAAAGGGCGCCACGTGT
		GGCGTTGTGAGTGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0004069	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
104	0	CCAAGCCGCGTGAGGGAGGAAGGCGCCAGGCGTCGT
		AAACCTCTTTTGCCGGGGAACAAAGGGCGCCACGTGT
		GGCGTTGTGAGTGTACCCGGAGAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0082399	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
105	1	CCAAGCCGCGTGAGGGAGGAAGGCGCCAGGCGTCGT
		AAACCTCTTTTGCCGGGGAACAAAGGGCGCCACGTGT
		GGCGTTGTGAGTGTACCCGGAGAAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000080	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
106	4	CCAAGCCGCGTGAGGGAATAAGGCGCCAAGCGTCGTA
		AACCTCTTTTGTCAGGGAACAAAAGCGGGCACGCGTG
		CCCGTCCGAGTGTACCTGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0115591	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
107	5	CCAAGCCGCGTGAAGGAAGAAGGTGCTAAGCATTGTA
		AACTTCTTTTGTCAGGGAACAAAGAGCGCGACGAGTC
		GCGCCGTGAGTGTACCTGAAGAAAAAGACATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0045985	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
108	0	CCAAGCCGCGTGAAGGAAGAAGGTGCTAAGCATTGTA
		AACTTCTTTTGTCAGGGAACAAAGAGCGCGACGAGTC
		GCGCCGTGAGTGTACCTGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0079809	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
109	8	CCAAGCCGCGTGAAGGAAGAAGGTGCTAAGCATTGTA
		AACTTCTTTTGTCAGGGAACAAAGAGCGCGACGAGTC
		GCGCCGTGAGTGTACCTGAAGAAAAGCATCGGCTAAC
		TCCGTGCC
SEQ_ID_NO_	R_U0000917	TGAGGAATATTGGTCAATGGTCGGAAGACTGAACCAG
110	0	CCAAGCCGCGTGAAGGAAGAAGGTGCTCGGCATCGTA
		AACTTCTTTTGTCAGGGAACAAAGGGCGGTACGTGTA
		CCGCTGTGAGTGTACCTGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0110215	TGAGGAATATTGGTCAATGGTCGGAAGACTGAACCAG
111	3	CCAAGCCGCGTGAAGGAAGAAGGTGCTCGGCATCGTA
		AACTTCTTTTGTCAGGGAACAAAGGGCGGTACGTGTA
		CCGCTGTGAGTGTACCTGAAGAAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000623	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
112	0	CCAAGCCGCGTGAAGGAAGAAGGTGCAGGGCATCGT
		AAACTTCTTTTGCCGGGGAACAATAAGCGGGACTAGT
		CCCGCGACGAGTGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0046534	TGAGGAATATTGGTCAATGGGCGTGAGCCTGAACCAG
113	4	CCAAGCCGCGTGAAGGAAGAAGGTGCAGGGCATCGT
		AAACTTCTTTTGCCGGGGAACAATAAGCGGGACTAGT
		CCCGCGACGAGTGTACCCGGAGAAAAGACATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000120	TGAGGAATATTGGTCAATGGTCGGGAGACTGAACCAG
114	2	CCAAGCCGCGTGAGGGATGGAGGTACAGAGTATCGTA
		AACCTCTTTTGTCAGGGAACAAAGGGCGCCACGTGTG
		GCGCTATGAGGGTACCTGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000138	TGAGGAATATTGGTCAATGGGAGAGATCCTGAACCAG
115	4	CCAAGCCGCGTGAGGGAAGACGGCACTACGTGTTGTA
		AACCTCTTTTGCCGGGGAACAAAAGCGGGGACGCGTC
		CCCGTCCGCGTGTACCCGGAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0080279	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
116	9	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGCGCCACGCGTG
		GCGAGATGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0080845	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
117	3	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGCGCCACGCGTG
		GCGAGATGAGAGTACCCGAAGAAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0002671	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
118	1	CCAAGCCGCGTGAAGGAAGACGGCCCTACGGGTTGTA
		AACTTCTTTTGTTGCAGGACAACACCCCGGACGCGTCC
		GGGCATGAGTGTATGCAAAGAAAAAGCATCGGCTAAC
		TCCGTGCC
SEQ_ID_NO_	R_U0000065	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
119	0	CCAAGCCGCGTGAGGGAATAAGGCCCTACGGGTCGTA
		AACCTCTTTTGTCGGGGAACAAAACCGGAGACGAGTC
		TCCGGCTGCGTGTACCCGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000083	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
120	9	CCAAGCCGCGTGAGGGAAGAAGGCGCTCAGCGTCGTA
		AACCTCTTTAGCCGGGGAACAAAGAGCTGCTCGGGAA
		GCAGCGTTGAGCGTACCCGGAGAATAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0115793	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
121	0	CCAAGTCGCGTGAGGGACGACGGTCCTACGGATTGTA
		AACCTCTTTTGCCGGGGAGCAATGCGCGGTACGCGTA
		CCGCGACGGAGAGTACCCGGAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0079842	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
122	0	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGCGCCACGCGTG
		GCGAGATGAGAGTACCCGAAGAAAAGACATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000193	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCAG
123	3	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAGGACTGCCACGAGTG
		GCAGGGCGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000149	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
124	1	CCAAGTCGCGTGAGGGAAGACGGTCTTACGGATTGTA
		AACCTCTTTTGCCGGGGAGCAAAGGGCGCCACGCGTG
		GCGTTTCGAGAGTACCCGGAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000647	TGAGGAATATTGGTCAATGGCCGAGAGGCTGAACCAG
125	6	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAAAGGCGTCACGTGTG
		ACGCTATGAGAGTACCCGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000150	TGAGGAATATTGGTCAATGGCCGGAAGGCTGAACCAG
126	2	CCAAGCCGCGTGAGGGAGGAAGGCGCAGAGCGTCGC
		AGACCTCTTTTGCCGGGGGACAAAAGGCCGGACTCGT
		CCGGTCCTGAGGGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000150	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCAG
127	4	CCAAGTCGCGTGAGGGATGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAATTCCGTTACGTGTAA
		CGGAGTCGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000060	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
128	9	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGCAGGGGAGCAAGGCACGGTACGTGTA
		CCGTGAAGGAGAGTACCCTGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000926	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
129	1	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCTCACGTGTG
		AGCGGAAGGAGAGTACCCGAAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0113699	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
130	2	CCAAGTCGCGTGAGGGAGGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCTCACGTGTG
		AGCGGAAGGAGAGTACCCGAAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000049	TGAGGAATATTGGTCAATGGCCGAAGGGCTGAACCAG
131	7	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGCCGGGGAGCAAAGGCGGTCACTGGTG
		ACCGGATGAGAGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000088	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
132	6	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCAGGGAGCAAGGAGGGCCACGAGTG
		GCGCTTCGGAGAGTACCTGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0114329	TGAGGAATATTGGTCAATGGCCGAGAGGCTGAACCAG
133	2	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAACAGCGCAACGCGCT
		TGCGCATTGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0080318	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
134	8	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGCGCCACGCGTG
		GCGAGATGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000878	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
135	2	CCAAGTCGCGTGAGGGAAGACGGCCCTATGGGTTGTA
		AACCTCTTTTGCCGGGGAGCAAAGAACCGCACGTGTG
		CGGTCTGGAGAGTACCCGGAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000140	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
136	6	CCAAGTCGCGTGAGGGAATAAGGCCCTAAGGGTCGTA
		AACCTCTTTTGCCGGGGAGCAATGGTTCGCTTGCGAG
		CGGACAGGGAGAGTACCCGGAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0003088	TGAGGAATATTGGTCAATGGCCGTAAGGCTGAACCAG
137	0	CCAAGTCGCGTGAGGGAAGACGGCCCTACGGGTTGTA
		AACCTCTTTTGCCGGGGAGCAAAAGGCGCCACGCGTG
		GCGTTTCGAGAGTACCCGGAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0045093	TGAGGAATATTGGTCAATGGGCGTAAGCCTGAACCAG
138	8	CCAAGTCGCGTGAGGGAAGACGGCCCTATGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCCCACGTGTG
		GGCGGAAGGAGAGTACCCGAAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000976	TGAGGAATATTGGTCAATGGGCGTAAGCCTGAACCAG
139	3	CCAAGTCGCGTGAGGGAAGACGGCCCTATGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCCCACGAGTG
		GGCGGAAGGAGAGTACCCGAAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0115549	TGAGGAATATTGGTCAATGGGCGTAAGCCTGAACCAG
140	5	CCAAGTCGCGTGAGGGAAGACGGCCCTATGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCCCACGAGTG
		GGCGGAAGGAGAGTACCCGAAGAAAAAGACATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U0079869	TGAGGAATATTGGTCAATGGGCGTAAGCCTGAACCAG
141	4	CCAAGTCGCGTGAGGGAAGACGGCCCTATGGGTTGTA
		AACCTCTTTTGTCGGGGAGCAAAGCCGCCCACGAGTG
		GGCGGAAGGAGAGTACCCGAAGAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0080236	TGAGGAATATTGGTCAATGGGCGGTAGCCTGAACCAG
142	0	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGCCGGGGAGCAAGGCCATGTACGTGTA
		CGTGGCCTGAGAGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0116278	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCAG
143	2	CCAAGTCGCGTGAGGGAAGACGGTCCTAAGGATTGTA
		AACCTCTTTTGTCAGGGAGCAAGGAGCGCCACGTGTG
		GCGCGGCGAGAGTACCTGAAGAAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000270	TGAGGAATATTGGTCAATGGGCGCGAGCCTGAACCAG
144	9	CCAAGTCGCGTGAGGGAAGACGGTCCTAAGGATTGTA
		AACCTCTTTTGTCAGGGAGCAAGGAGCGCCACGTGTG
		GCGCGGCGAGAGTACCTGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000523	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
145	2	CCAAGTCGCGTGAGGGAAGACAGTCCTATGGATTGTA
		AACCTCTTTTGCCGGGGAGCAAAGAGCGGCACGTGTG
		CCGCGCCGAGAGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000030	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
146	5	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGCCGGGGAGCAAAGAGCGGCACGTGTG
		CCGCGCCGAGAGTACCCGGAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0000682	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
147	1	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAACGAAGGCACGTGTGC
		CAGAAGCGAGATTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0119940	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
148	5	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAACGAAGGCACGTGTGC
		CAGAAGCGAGATTACCCGAAGAAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000615	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
149	0	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAACGAAGGCACGTGTGC
		CTGAAGCGAGATTACCCGAAGAAAAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000020	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
150	6	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGGCCACGTGTGG
		TCAAAAGCGAGAGTACCCGAAGAAAAAGCATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0115067	TGAGGAATATTGGTCAATGGGCGGGAGCCTGAACCAG
151	3	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAAGAGGCCACGTGTGG
		TCAAAAGCGAGAGTACCCGAAGAAAAAGACATCGGC
		TAACTCCGTGCC
SEQ_ID_NO_	R_U0080581	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
152	1	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAGGATCCGCACGAGTG
		CGGAGGCGAGAGTACCCGAAGAAAAAGCATCGGCTA
		ACTCCGTGCC
SEQ_ID_NO_	R_U0119947	TGAGGAATATTGGTCAATGGGCGGAAGCCTGAACCAG
153	1	CCAAGTCGCGTGAGGGAAGACGGTCCTATGGATTGTA
		AACCTCTTTTGTCGGGGAGCAAGGATCCGCACGAGTG
		CGGAGGCGAGAGTACCCGAAGAAAAAGACATCGGCT
		AACTCCGTGCC
SEQ_ID_NO_	R_U0000006	TGAGGAATATTGGTCAATGGGCGAGAGCCTGAACCAG
154	8	CCAAGTCGCGTGAGGGAAGAATGGTCTATGGCCTGTA
		AACCTCTTTTGTCAGGGAAGAATAAGGATGACGAGTC
		ATTCGATGCCAGTACTTGACGAATAAGCATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0000555	TGAGGAATATTGGTCAATGGACGCAAGTCTGAACCAG
155	9	CCATGCCGCGTGCAGGAAGACGGCTCTATGAGTTGTA
		AACTGCTTTTGTACGAGGGTAAACCCGGATACGTGTA
		TCCGGCTGAAAGTATCGTACGAATAAGGATCGGCTAA
		CTCCGTGCC
SEQ_ID_NO_	R_U0080196	CTAAGGATATTCCGCAACGGGCGGAAGCCCGGCGGAG
156	1	CGACGCCGCGTGGACGAGGAAGGCCGGAAGGTTGCA
		GAGTCCTTTTGCGGGGGAAGAAGGAGCCGCGGAGGG
		AATGCCGCGGCGGCGACCGAACCCCGCGAATAAGGG
		GCGGCTAATTACGTGCC
SEQ_ID_NO_	R_U0000012	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAG
157	6	CGACGCCGCGTGCGGGATGGAGGCCTTCGGGTTGTAA
		ACCGCTTTTGTTCAAGGGCAAGGCACGGCTTCGGGCC
		GTGTTGAGTGGATTGTTCGAATAAGCACCGGCTAACT
		ACGTGCC
SEQ_ID_NO_	R_U0016410	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
158	5	CGACGCCGCGTGGGTGAAGAAGTATTTCGGTATGTAA
		AGCCCTATCAGCAGGGAAGAAAAAGACGGTACCTGA
		CTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0011807	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
159	8	CGACGCCGCGTGAAGGAAGAAGTATTTCGGTATGTAA
		ACTTCTATCAGCAGGGAAGAAAATGACGGTATCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0114837	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
160	6	CGACGCCGCGTGGGTGAAGAAGTATTTCGGTATGTAA
		AGCCCTATCAGCAGGGAAGAAAATGACAGTACCTGAA
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0044400	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
161	2	CGACGCCGCGTGGGTGAAGAAGTATTTCGGTATGTAA
		AGCCCTATCAGCAGGGAAGAAAGAAGACGGTACCTG
		AGTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0113039	TGGGGAGTATTGCACAATGGGGGAAACCCGTGATGCA
162	6	GCGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTA
		AAGCTCTATCAGCAGGGAAGAAAATAGACGGTACCTG
		ACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0001158	TGGGGGATATTGGACAATGGGGGGAACCCTGATCCAG
163	2	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAGAAATGACGGTACCT
		GACCAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0043988	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
164	8	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTACGTAA
		AGCTCTATCAGCAGGGAAGAAAAAGAAATGACGGTA
		CCTGATTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0116361	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
165	7	CAATGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAAAAGACGGTACCTG
		ACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0002930	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
166	6	CAATGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAAAAGACGGTACCTG
		ACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0079798	TGGGGAATATTGCACAATGGAGGAAACTCTGATGCAG
167	5	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTACGTAA
		AGCTCTATCAGCAGGGAAGAAAAAATGACGGTACCTG
		ACTAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0117359	TGGGGAATATTGCACAATGGAGGAAACTCTGATGCAG
168	4	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTACGTAA
		AGCTCTATCAGCAGGGAGAAAAAAATGACGGTACCTG
		ACTAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0000928	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
169	2	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAGATGACAGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016528	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
170	8	CAACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0000348	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
171	1	CGATGCCGCGTGGAGGAAGAAGGTTTTCGGATTGTAA
		ACTCCTGTCTTAAAGGACGATAATGACGGTACTTTAG
		GAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000354	TGGGGAATATTGCACAATGGGCGCAAGCCTGATGCAG
172	8	CGACGCCGCGTGAGTGAGGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAGAATGACGGTACCTGA
		CTAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0079847	TGGGGAATATTGCACAATGGAGGGAACTCTGATGCAG
173	2	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTATGTAA
		AGCTCTGTCAGCAGGGAAGAAAGTGACGGTACCTGAA
		AAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0080400	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
174	5	CGACGCCGCGTGAGTGAAGAAATATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAG
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016481	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
175	4	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTATGTAA
		AGCTCTATCAGCAAGGAAGAAAAAAGACGGTACTTGA
		CTAAGAAGCCCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0050740	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
176	9	CGACGCCGCGTGGGTGAAGAAGTATTTCGGTATGTAA
		AGCCCTATCAGCAGGGAAGAAGATGACAGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000995	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
177	2	CGACGCCGCGTGGGTGAAGGAGTACTCCGGTATGTAA
		AGCCCTATCGGCAGGGAAGAAGATGACGGTACCTGAC
		TAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0083254	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
178	9	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAGTGACAGTACCTGAG
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0001347	TGGGGGATATTGGACAATGGGGGGAACCCTGATCCAG
179	6	CGACGCCGCGTGAGTGAAGAAGTATCTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAGAAATGACGGTACCT
		GAGTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000001	TGGGGGATATTGGACAATGGGGGGAACCCTGATCCAG
180	2	CGACGCCGCGTGAGTGAAGAAGTATCTCGGTATGTAA
		AGCTCTGTCAGCAGGGAAGAAAGAAATGACGGTACCT
		GACCAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080806	TGGGGGATATTGGACAATGGGGGGAACCCTGATCCAG
181	5	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTGTCAGCAGGGAAGAAAGAAATGACGGTACCT
		GAAGAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0081662	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
182	5	CGACGCCGCGTGGGTGAAGGAGTGCTTCGGCATGTAA
		AGCCCTATCGGCAGGGAAGAAGAAGGACGGTACCTG
		ACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016460	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
183	5	CGACGCCGCGTGGGTGAAGAAGCGCCCCGGCGCGTAA
		AGCCCTATCGGCAGGGAAGAAGATGACGGTACCTGGC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0023209	GGGGATATTGCACAATGGGGGAACCCGTGATGCAGCG
184	6	ACGCCGCGTGGGTGAAGAAGCGCCCCGGCGCGTAAA
		GCCCTATCGGCAGGGAAGAAGATGACGGTACCTGGCT
		AAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0003150	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
185	2	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGAACGAAGAAGACGGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0113068	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
186	3	CGACGCCGCGTGAGTGAAGAAGTAATTCGTTACGTAA
		AGCTCTATCAGCAGGAAAGAAAGAAGACGGTACCTG
		ACTAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0113935	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
187	5	CGACGCCGCGTGAGCGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCGGGGAAGAGAATGACGGTACCCGAC
		TAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0085159	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
188	9	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAGATGACAGTACCTGAA
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0001004	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
189	7	CGACGCCGCGTGAGCGAGGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016413	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
190	5	CAACGCCGCGTGAGCGATGAAGGTCTTCGGATTGTAA
		AGCTCTGTCGCAGGGGACGAAGTATGACGGTACCCTG
		TAAGAAAGCCCCGGCAAACTACGTGCC
SEQ_ID_NO_	R_U0003405	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
191	0	CGACGCCGCGTGAGCGAAGAAGTATCTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAGAATGACGGTACCTGA
		GTAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0113967	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
192	0	CGACGCCGCGTGAGCGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAA
		CAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0003367	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
193	0	CAACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCACCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0003369	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
194	3	CGACGCCGCGTGAGTGAAGGAGTACTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAGCAAGACGGTACCTGA
		CCAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000258	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
195	3	CGACGCCGCGTGAGCGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0004412	TGGGGAATATTGGGCAATGGAGGCAACTCTGACCCAG
196	9	CAACGCCGCGTGAGCGATGAAGGTCTTCGGATTGTAA
		AGCTCTTTAAGTGGGGACGAAGAAAGTGACTGTACCC
		ACAGAATAAGCCTCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0004265	TGGGGAATATTGGGCAATGGAGGAAACTCTGACCCAG
197	3	CAACGCCGCGTGAATGATGAAGGTCTTCGGATTGTAA
		AGTTCTTTTCTAAGGGAAGAAGAAAGTGACGGTACCT
		TAGGAATAAGCCTCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0085532	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
198	8	CAATGCCGCGTGGGTGAAGAAGTACCCCGGTATGTAA
		AGCCCTATCAGCAGGGAAGAAAATGACGGTACCTGGC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016419	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
199	6	CGACGCCGCGTGAGCGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAAGGAAGATAATGACGGTACTTGAC
		TAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0016425	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAG
200	6	CAACGCCGCGTGAAGGAAGAAGGGTTTCGGCTCGTAA
		ACTTCTATCAACAGGGACGAAGGAAGTGACGGTACCT
		GAATAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000307	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
201	9	CAACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCTCCGGCTAAATACGTGCC
SEQ_ID_NO_	R_U0000240	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
202	4	CGACGCCGCGTGGAGGAAGAAGGCCCTCGGGTTGTAA
		ACTCCTGTCTTTGGGGACGATAATGACGGTACCCAAG
		GAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080437	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
203	5	CGACGCCGCGTGGAGGAAGAAGGCCCTCGGGTTGTAA
		ACTCCTGTCTTCGGGGACGATAATGACGGTACCCGAG
		GAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0044387	TGGGGGATATTGCACAATGGGGGGAACCCTGATGCAG
204	2	CGACGCCGCGTGAGCGAAGAAGATCTTCGGATTGTAA
		AGCTCTGTCTTAGGGGACGATGATGACGGTACCCTGA
		GAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000012	TGGGGGATATTGCGCAATGGGGGCAACCCTGACGCAG
205	8	CAACGCCGCGTGAAGGATGAAGGTTTTCGGATTGTAA
		ACTTCTTTTCTTAAGGACGAAATTTGACGGTACTTAAG
		GAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000277	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
206	7	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTAAGAGGGACGAAGGAAGTGACGGTACCT
		CTTGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000116	TGAGGGATATTGGTCAATGGGGGAAACCCTGAACCAG
207	6	CAACGCCGCGTGAGGGAAGACGGTCTTCGGATTGTAA
		ACCTTTGTCCTCTGTGAAGATAATGACGGTAGCAGAG
		GAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000208	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
208	7	CAACGCCGCGTGAAGGAAGAAGGTCTTCGGATTGTAA
		ACTTTTGTCCTTGGTGAAGATAATGACGGTAGCCAAG
		GAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000809	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
209	8	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGTCAGGGAAGAGCAGAAGACGGTACCTG
		ACGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000098	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
210	1	CGACGCCGCGTGTGGGAAGACGGTCCTCTGGATTGTA
		AACCACTGTCCCCAGGGACGAAGATGACGGTACCTGG
		GGAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0043629	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
211	2	CGATGCCGCGTGGAGGAAGAAGGTTTTCGGATTGTAA
		ACTCCTGTCGACAGGAAAGAAAAAGGACTGTACCTGT
		CAAGAAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000255	TGGGGAATATTGCACAATGGGGGGAACCCTGATGCAG
212	1	CGATGCCGCGTGGAGGAAGAAGGTTTTCGGATTGTAA
		ACTCCTGTCTTAAAGGACGATAATGACGGTACTTTAG
		GAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016429	TGGGGAATATTGCACAATGGAGGAAACTCTGATGCAG
213	7	CGATGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTCTTAAGGGACGATAATGACGGTACCTTAG
		GAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080693	TGGGGGATATTGCACAATGGAGGGAACTCTGATGCAG
214	7	CGATGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTGGACAGAGACGATAATGACGGTATCTGTC
		AAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000272	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
215	3	CGATGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTGGAGGGGGACGATAATGACGGTACCCCTT
		AAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000487	TGGGGGATATTGGACAATGGGGGAAACCCTTATCCAG
216	8	CGACGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTCAGCGGGGACGATAATGACGGTACCCGCG
		GAGGAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0114298	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
217	2	CGACGCCGCGTGAAGGAAGACGGTCTTCGGATTGTAA
		ACTTTAGTACTCAGGGACGAAGAAATGACGGTACCTG
		AGGTTAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080688	TGGGGGATATTGCGCAATGGGGGAAACCCTGACGCAG
218	4	CAACGCCGCGTGAAGGAAGAAGGTTTTCGGATTGTAA
		ACTTCTTTTATTAAGGACGAAAGATGACGGTACTTAAT
		GAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0081053	TGGGGAATATTGGGCAATGGACGCAAGTCTGACCCAG
219	1	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGTCAGGGAAGAGAAGAAGACGGTACCTG
		ACGAACAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000014	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
220	9	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGACAGGGAAGAGCAGAAGACGGTACCTG
		TCGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000450	TGGGGGATATTGCGCAATGGGGGCAACCCTGACGCAG
221	1	CAACGCCGCGTGAAGGATGAAGGTTTTCGGATTGTAA
		ACTTCTTTTATTAAGGACGAATTTTGACGGTACTTAAT
		GAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0013288	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
222	2	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTAAGAGGGAAGAGCAGAAGACGGTACCTC
		TTGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080038	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCAG
223	7	CAACGCCGCGTGAGGGAAGAAGGCTTTCGGGTTGTAA
		ACCTCTTTTACCAGGGACGAAGGACGTGACGGTACCT
		GGAGAAAAAGCAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000090	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCAG
224	8	CAACGCCGCGTGAAGGAAGAAGGCCTTCGGGTTGTAA
		ACTTCTTTTACCAGGGACGAAGGACGTGACGGTACCT
		GGAGAAAAAGCAACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0020438	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
225	6	CAACGCCGCGTGAAGGAAGAAGGCCTTCGGGTTGTAA
		ACTTCTTTTAAGAGGGACGAAGAAAGTGACGGTACCT
		CTTGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0079945	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
226	3	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGAGAGGGACGAAACAAATGACGGTACCT
		CTTGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080607	TGGGGAATATTGGGCAATGGGCGGAAGCCTGACCCAG
227	1	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTCTTGGGGACGAAGAAAGTGACGGTACCC
		AAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0113290	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
228	7	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGAGGGGGACGAAGGATGTGACGGTACCC
		CTTGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0046333	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
229	7	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTCTTGGGGACGAAGAAAGTGACGGTACCC
		GAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0081299	TGGGGAATATTGCACAATGGGGGAAACCCTGATGCAG
230	4	CGACGCCGCGTGGGTGAAGAAGTATTTCGGTATGTAA
		AGCCCTATCAGCAGGGAAGATCATGACGGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0001001	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
231	8	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTCTGAGGGACGAAGCAAGTGACGGTACCT
		TAGGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0016472	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
232	0	CAACGCCGCGTGAAGGAAGAAGGCTTTCGGGTTGTAA
		ACTTCTTTTGACAGGGAAGAGGAGAAGACGGTACCTG
		TCGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000441	TGGGGAATATTGGGCAATGGGCGCAAGCCTGACCCAG
233	8	CAACGCCGCGTGAAGGAAGAAGGCCCTCGGGTTGTAA
		ACTTCTTTTATCAGGGACGAAGAAGTGACGGTACCTG
		ATGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0020815	TGGGGAATATTGCGCAATGGGGGAAACCCTGACGCAG
234	3	CAACGCCGCGTGATTGAAGAAGGCCTTCGGGTTGTAA
		AGATCTTTAATCGGGGACGAATTTTGACGGTACCCGA
		AGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0003087	TGGGGAATATTGCGCAATGGGGGAAACCCTGACGCAG
235	0	CAACGCCGCGTGATTGAAGAAGGCCCTCGGGTTGTAA
		AGATCTTTAATCGGGGACGAAGAATGACGGTACCCGA
		AGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0083779	TGGGGAATATTGCGCAATGGGGGAAACCCTGACGCAG
236	7	CAACGCCGCGTGAGTGAAGAAGGCCTTCGGGTTGTAA
		AGCTCTTTAATCAGGGACGAAGAACGACGGTACCTGA
		AGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0044980	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
237	4	CAACGCCGCGTGAAGGAAGAAGGTCTTCGGATTGTAA
		ACTTCTTTTATCAGGGACGAAGGAAGTGACGGTACCT
		GATGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0043633	TCGGGAATATTGCGCAATGGAGGCAACTCTGACGCAG
238	2	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCCACAGGGAAGAAAAGGACTGTACCTGTG
		AAGAAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000343	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
239	5	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCCACAGGGAAGATAAAAGACTGTACCTGT
		GAAGAAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0019867	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
240	3	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGATAGGGAAGAAAAAAGACTGTACCTAT
		CAAGAAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000272	TCGGGAATATTGCGCAATGGAGGGAACTCTGACGCAG
241	0	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTTTAGTCAGGGAAGAAAGCAGACGGTACCTGA
		AGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0019570	TCGGGAATATTGCACAATGGAGGAAACTCTGATGCAG
242	7	TGACGCCGCGTGCAGGAAGAAGGTTTTCGGATTGTAA
		ACTGCTTTAGACAGGGAAGAAAAAAGACAGTACCTGT
		AGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000268	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
243	6	TGACGCCGCGTATAGGAAGAAGTTTTTCGGAATGTAA
		ACTATTGTCGTTAGGGAAGAGAAAGGACAGTACCTAA
		GGAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000895	TCGGGAATATTGCGCAATGGAGGGAACTCTGACGCAG
244	9	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGTTAGGGAAGAAAAAAGACAGTACCTAA
		GGAGGAAGCCCCGGCTAACTATGTGCC
SEQ_ID_NO_	R_U0003435	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
245	1	TGACGCCGCGTATAGGAAGAAGGTCTTCGGATTGTAA
		ACTATTGTCGTTAGGGAAGAGAAAGGACAGTACCTAA
		GGAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0043700	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
246	9	TGACGCCGCGTGCAGGAAGAAGGTTTTCGGATTGTAA
		ACTGCTTTAGACAGGGAAGAAACAAATGACAGTACCT
		GTAGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0003248	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
247	6	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGTGAGGGAAGAAATTGACAGTACCTCAG
		GAGGAAGCTCCGGCTAACTATGTGCC
SEQ_ID_NO_	R_U0000099	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
248	9	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGTTAGGGAAGAGAAAGGACAGTACCTAA
		GGAGGAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000220	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
249	1	TGACGCCGCGTGCAGGAAGAAGGTTTTCGGATTGTAA
		ACTGCTTTAGACAGGGAAGAAAGAAATGACGGTACCT
		GTAGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000189	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
250	1	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGTTAGGGAAGATAAAAGACTGTACCTAA
		GGAGGAAGCCCCGGCTAACTATGTGCC
SEQ_ID_NO_	R_U0080366	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
251	5	TGACGCCGCGTATAGGAAGAAGTTTTTCGGAATGTAA
		ACTATTGTCATTAGGGAAGAGAAAGGACGGTACCTAA
		GGAGGAAGCCCCGGCTAACTATGTGCC
SEQ_ID_NO_	R_U0002711	TCGGGAATATTGCGCAATGGAGGAAACTCTGACGCAG
252	1	TGACGCCGCGTATAGGAAGAAGGTTTTCGGATTGTAA
		ACTATTGTCGTTAGGGAAGAAAAAAGACAGTACCTAA
		GGAGGAAGCCCCGGCTAACTATGTGCC
SEQ_ID_NO_	R_U0045415	TTGGGAATATTGGACAATGGAGGAAACTCTGATCCAG
253	7	TGACGCCGCGTGAAGGAAGAAGGTCTTCGGATTGTAA
		ACTTATTTTGTCAGGGAAGAATAAATGACTGTACCTG
		AAGAAAAAGCACCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0008017	TGGGGAATATTGCGCAATGGGGGAAACCCTGACGCAG
254	4	CAACGCCGCGTGCAGGAAGAAGGTCTTCGGATTGTAA
		ACTGTTGTCGCAGGGGAAGAAGACAGTGACGGTACCC
		TGTGAGAAAGTCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080330	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
255	2	CAACGCCGCGTGGAGGAAGAAGGTTTTCGGATCGTAA
		ACTCCTGTCCTAAGAGACGAGGAAGAGACGGTATCTT
		AGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0003220	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
256	8	CAACGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTCCTAAGTGACGAAGGAAGTGACGGTAGCT
		TAGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000111	TGGGGAATATTGGGCAATGGGCGAAAGCCTTACCCAG
257	6	CAACGCCGCGTGAGGGAAGAAGGTTTTCGGATTGTAA
		ACCTCTGTCCTGGGGGACGAAGGAAGTGACGGTACCC
		CGGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080770	TGGGGAATATTGGGCAATGGGGGAAACCCTGACCCAG
258	4	CAACGCCGCGTGAAGGAAGAAGGTTTTCGGATCGTAA
		ACTTCTATCCTTGGTGAAAATGATGATGGTAGCCAAG
		AAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000027	TGGGGAATATTGGGCAATGGGCGAAAGCCTGACCCAG
259	2	CAACGCCGCGTGAGGGAAGAAGGGTTTCGGCTCGTAA
		ACCTCTGTCCTATGGGACGAAGGAAGTGACGGTACCA
		TAGGAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0080527	TGGGGAATATTGCACAATGGGCGAAAGCCTGATGCAG
260	7	CAACGCCGCGTGAGCGAAGAAGGTCTTCGGATCGTAA
		AGCTCTGTCCTTGGGGAAGATAATGACGGTACCCAAG
		GAGGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0113623	TGGGGAATATTGGGCAATGGAGGCAACTCTGACCCAG
261	8	CAACGCCGCGTGAATGAAGAAGGTCCTAGGATTGTAA
		AGTTCTTTTATGATAGACGAATAAAATGACGGTATAT
		CATGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0084863	TGGGGAATATTGGGCAATGGAGGCAACTCTGACCCAG
262	9	CAACGCCGCGTGAATGAAGAAGGCCTTCGGGTTGTAA
		AGTTCTTTAATGGGGGACGAAGAAAGTGACGGTACCC
		CAAGAATAAGCCACGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0000424	TGGGGGATATTGCACAATGGGGGAAACCCTGATGCAG
263	9	CGACGCCGCGTGAGTGAAGAAGTATTTCGGTATGTAA
		AGCTCTATCAGCAGGGAAGAAAATGACGGTACCTGAC
		TAAGAAGCCCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0001209	TTAGGAATATTCGTCAATGGGGGAAACCCTGAACGAG
264	6	CAATGCCGCGTGAGTGATGACGGTCTTTATGATTGTA
		AAACTCTGTTGTAAGGAAAGAACCCTTATCATAGGAA
		ATGATGATAAGTTGACGGTACCTTACCAGAAAGCCCC
		GGCTAACTACGTGCC
SEQ_ID_NO_	R_U0115212	TAGGGAATTTTCGGCAATGGGGGGAACCCTGACCGAG
265	2	CAACGCCGCGTGAACGAAGAAGTTATTCGTAATGTAA
		AGTTCTTTTATCAGGGAAGAAAAGAAGGGAATTGACG
		GTACCTGATGAATAAGCTCCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0112319	TGGGGAATCTTCCGCAATGGGCGAAAGCCTGACGGAG
266	9	CGACGCCGCGTGAGTGAAGAAGGTCTTCGGACCGTAA
		AGCTCTTTTGTTGCAGGCGAAAGGACTTAAGAGGAAA
		TGCTTAAGTTAAGACGGTATGGAACGAATAAGCCACG
		GCTAACTACGTGCC
SEQ_ID_NO_	R_U0000073	TAGGGAATCTTTCACAATGGGCGAAAGCCTGATGGAG
267	7	CAACGCCGCGTGCAGGATGAAGGCCTTCGGGTTGTAA
		ACTGCTTTTATAAGCGAGAAATATGATGGTAACTTAT
		GAATAAGGATCGGCTAACTACGTGCC
SEQ_ID_NO_	R_U0082204	TGGGGAATTTTGGACAATGGACGGAAGTCTGATCCAG
268	0	CAACGCAGCGTGAAGGACGAAGGTTCTCGGATTGTAA
		ACTTCTTTTGCAGGGGAAGAAAAAAATGACGGTACCC
		TGTGAATAAGCCACGGCTAACTACGTGCC

In the above detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise. The illustrative embodiments described in the detailed description, drawings, and claims are not meant to be limiting. Other embodiments may be used, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily understood that the aspects of the present disclosure, as generally described herein, and illustrated in the Figures, may be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein.

The present disclosure is not to be limited in terms of the particular embodiments described in this application, which are intended as illustrations of various aspects. Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.

It will be understood by those within the art that, in general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” the term “includes” should be interpreted as “includes but is not limited to,” etc.). It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”

In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.

As will be understood by one skilled in the art, for any and all purposes, such as in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc. As will also be understood by one skilled in the art all language such as “up to,” “at least,” and the like include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.

From the foregoing, it will be appreciated that various embodiments of the present disclosure have been described herein for purposes of illustration, and that various modifications may be made without departing from the scope and spirit of the present disclosure. Accordingly, the various embodiments disclosed herein are not intended to be limiting, with the true scope and spirit being indicated by the following claims.

Claims

1. A method for increasing a first gut microbiota population while simultaneously decreasing a second gut microbiota population in a subject having obesity, diabetes or insulin insensitivity to increase short-chain fatty acid level in the subject or reducing subject insulin sensitivity, comprising administering to the subject berberine at a dosage of from about 50 mg/Kg body weight to about 400 mg/Kg body weight, wherein the first gut microbiota population comprises, Allobaculum, Bacteroides, Blautia, Butyricicoccus, Dorea, Holdemania, Lawsonia, Parabacteroides, Phascolarctobacterium, Sedimentibacter, or a combination thereof; wherein the second gut microbiota population comprises Anaeroplasma, Bifidobacterium, Butyrivibrio, Coprococcus, Fastidiosipila, Marvinbryantia, Oribacterium, Roseburia, Ruminococcus, TM7_genera_incertae_sedis, or a combination thereof.

2. The method of claim 1, wherein the first gut microbiota population comprises a bacterium whose V3 region of 16S rRNA gene sequence has at least about 95% similarity with a nucleic acid sequence selected from a group consisting of SEQ ID NO: 1-93.

3. The method of claim 1, wherein the second gut microbiota population comprises a bacterium whose V3 region of 16S rRNA gene sequence has at least about 95% similarity with a nucleic acid sequence selected from a group consisting of SEQ ID NO: 94-268.